Identification

Name
Metipranolol
Accession Number
DB01214  (APRD00668)
Type
Small Molecule
Groups
Approved
Description

A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent. [PubChem]

Structure
Thumb
Synonyms
  • (+-)-Metipranolol
  • Acetic acid 4-(2-hydroxy-3-isopropylamino-propoxy)-2,3,6-trimethyl-phenyl ester
  • Metipranolol
  • Metipranololum
Product Ingredients
IngredientUNIICASInChI Key
Metipranolol hydrochlorideFBW237ALKD36592-77-5BLWNYSZZZWQCKO-UHFFFAOYSA-N
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetipranololSolution / drops3 mg/mLOphthalmicFalcon Pharmaceuticals2001-08-09Not applicableUs
International/Other Brands
Betanol / Disorat / OptiPranolol / Trimepranol
Categories
UNII
X39AL81KEB
CAS number
22664-55-7
Weight
Average: 309.4006
Monoisotopic: 309.194008357
Chemical Formula
C17H27NO4
InChI Key
BQIPXWYNLPYNHW-UHFFFAOYSA-N
InChI
InChI=1S/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3
IUPAC Name
4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}-2,3,6-trimethylphenyl acetate
SMILES
CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1

Pharmacology

Indication

Indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.

Associated Conditions
Pharmacodynamics

Metipranolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Metipranolol is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Metipranolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Metipranolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.

Mechanism of action

Although it is known that metipranolol binds the beta1 and beta2 adrenergic receptors, the mechanism of metipranolol's action is not known. It has no significant intrinsic sympathomimetic activity, and has only weak local anesthetic (membrane-stabilizing) and myocardial depressant activity. It appears that the ophthalmic beta-adrenergic blocking agents reduce aqueous humor production, as demonstrated by tonography and fluorophotometry. A slight increase in aqueous humor outflow may be an additional mechanism.

TargetActionsOrganism
ABeta-2 adrenergic receptor
antagonist
Human
ABeta-1 adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Metipranolol Action PathwayDrug action
Metipranolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Metipranolol.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Metipranolol.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Metipranolol.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Metipranolol.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Metipranolol can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineAcepromazine may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Metipranolol.Approved
AcetohexamideMetipranolol may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Acetylcholine.Approved
AcetyldigitoxinMetipranolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinMetipranolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Metipranolol.Approved
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Metipranolol.Experimental, Investigational
AlaproclateThe serum concentration of Metipranolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Metipranolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metipranolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Metipranolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Metipranolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
AliskirenMetipranolol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Metipranolol.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Metipranolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Metipranolol.Approved
AmbrisentanMetipranolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineMetipranolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Metipranolol.Approved
AmiodaroneThe therapeutic efficacy of Metipranolol can be increased when used in combination with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Metipranolol.Approved
AmobarbitalThe serum concentration of Metipranolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Metipranolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Metipranolol.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Metipranolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Metipranolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Metipranolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Metipranolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Metipranolol.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Metipranolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Metipranolol.Approved
ApremilastApremilast may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Arecoline.Experimental
AripiprazoleAripiprazole may increase the hypotensive activities of Metipranolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Metipranolol.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Metipranolol.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Metipranolol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Metipranolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Metipranolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Metipranolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Metipranolol is combined with Azilsartan medoxomil.Approved, Investigational
BalsalazideBalsalazide may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
BarbexacloneThe serum concentration of Metipranolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Metipranolol can be decreased when it is combined with Barbital.Illicit
BarnidipineMetipranolol may increase the antihypertensive activities of Barnidipine.Approved
BendazacBendazac may decrease the antihypertensive activities of Metipranolol.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Metipranolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Metipranolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Metipranolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Metipranolol.Withdrawn
BenzphetamineThe therapeutic efficacy of Benzphetamine can be decreased when used in combination with Metipranolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Metipranolol.Approved
BepridilMetipranolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantMetipranolol may increase the bradycardic activities of Beractant.Approved
BetaxololBetaxolol may increase the hypotensive activities of Metipranolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Metipranolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the hypotensive activities of Metipranolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Metipranolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Metipranolol.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Metipranolol.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Metipranolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Metipranolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Metipranolol.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Metipranolol.Approved, Investigational
BQ-123Metipranolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Metipranolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Metipranolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Metipranolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Metipranolol.Approved
BromocriptineMetipranolol may increase the vasoconstricting activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Metipranolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Metipranolol.Approved, Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Metipranolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Metipranolol.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Metipranolol.Approved, Investigational
BupranololMetipranolol may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Metipranolol can be decreased when combined with Bupropion.Approved
CabergolineMetipranolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Metipranolol.Experimental
CafedrineMetipranolol may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Caffeine.Approved
CalfactantMetipranolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Metipranolol is combined with Canagliflozin.Approved
CandesartanMetipranolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Metipranolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Metipranolol.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Metipranolol.Approved
CarbamoylcholineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Metipranolol.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Metipranolol.Approved, Investigational
CarbutamideMetipranolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Metipranolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved, Withdrawn
CarvedilolCarvedilol may increase the hypotensive activities of Metipranolol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Metipranolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
CeliprololMetipranolol may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibMetipranolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Metipranolol can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Metipranolol.Experimental
ChlorpromazineChlorpromazine may increase the hypotensive activities of Metipranolol.Approved, Investigational, Vet Approved
ChlorpropamideMetipranolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Metipranolol.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Metipranolol.Approved
CicletanineMetipranolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilMetipranolol may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Metipranolol.Approved, Investigational
CimetidineThe metabolism of Metipranolol can be decreased when combined with Cimetidine.Approved, Investigational
ClemastineThe metabolism of Metipranolol can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Metipranolol.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Metipranolol.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Metipranolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Metipranolol.Approved
CloranololMetipranolol may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Metipranolol.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Metipranolol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Metipranolol.Vet Approved
CrizotinibMetipranolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Metipranolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
CyclopenthiazideMetipranolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of hyperkalemia can be increased when Metipranolol is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinMetipranolol may increase the bradycardic activities of Cymarin.Experimental
DapagliflozinThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Metipranolol can be increased when it is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Metipranolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Metipranolol.Approved
DelaprilMetipranolol may increase the hypotensive activities of Delapril.Investigational
DemecariumDemecarium may increase the bradycardic activities of Metipranolol.Approved
DeserpidineMetipranolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Metipranolol.Approved
DeslanosideMetipranolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Metipranolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Metipranolol.Approved, Vet Approved
DexniguldipineMetipranolol may increase the hypotensive activities of Dexniguldipine.Experimental
DiazoxideDiazoxide may increase the hypotensive activities of Metipranolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Metipranolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Metipranolol.Approved, Investigational
DiethylnorspermineMetipranolol may increase the hypotensive activities of Diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Metipranolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
DigitoxinMetipranolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinMetipranolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Metipranolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Metipranolol.Approved, Investigational
DihydroergotamineMetipranolol may increase the vasoconstricting activities of Dihydroergotamine.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Metipranolol.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe metabolism of Metipranolol can be decreased when combined with Diphenhydramine.Approved, Investigational
DipivefrinDipivefrin may increase the bradycardic activities of Metipranolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Metipranolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Metipranolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Metipranolol.Experimental
DonepezilDonepezil may increase the bradycardic activities of Metipranolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Metipranolol.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Metipranolol.Approved
DronedaroneDronedarone may increase the bradycardic activities of Metipranolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Metipranolol.Withdrawn
DuloxetineMetipranolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Metipranolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Metipranolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Metipranolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Metipranolol.Approved
EfonidipineMetipranolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Metipranolol is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
EnalaprilatMetipranolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Metipranolol.Experimental
EpanololMetipranolol may increase the hypotensive activities of Epanolol.Experimental
EpibatidineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Epibatidine.Experimental
EpirizoleEpirizole may decrease the antihypertensive activities of Metipranolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Metipranolol.Approved
EpoprostenolMetipranolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanEprosartan may increase the hypotensive activities of Metipranolol.Approved
Ergoloid mesylateMetipranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineMetipranolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineMetipranolol may increase the vasoconstricting activities of Ergotamine.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Metipranolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metipranolol.Approved, Investigational
EtanerceptEtanercept may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Metipranolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Metipranolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Metipranolol.Approved
EtoperidoneThe serum concentration of Metipranolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Metipranolol.Investigational, Nutraceutical
ExisulindExisulind may decrease the antihypertensive activities of Metipranolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Metipranolol.Experimental
FelodipineFelodipine may increase the hypotensive activities of Metipranolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Metipranolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Metipranolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Metipranolol.Approved
FentanylFentanyl may increase the bradycardic activities of Metipranolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Metipranolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Metipranolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Metipranolol.Experimental
Ferulic acidMetipranolol may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Metipranolol.Approved, Investigational
FingolimodMetipranolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Floctafenine.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Metipranolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Metipranolol.Experimental
FluoxetineThe serum concentration of Metipranolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Metipranolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
FluvoxamineThe metabolism of Metipranolol can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Metipranolol.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Metipranolol.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Metipranolol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Metipranolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Metipranolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Metipranolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Metipranolol.Approved, Investigational, Nutraceutical
GitoformateMetipranolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideMetipranolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideMetipranolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMetipranolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMetipranolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneMetipranolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideMetipranolol may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideMetipranolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Metipranolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Metipranolol.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Metipranolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Metipranolol.Approved
GuanazodineMetipranolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Metipranolol.Approved
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Metipranolol.Approved, Investigational
GuanoclorMetipranolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzMetipranolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanMetipranolol may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Metipranolol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Metipranolol.Experimental
HexamethoniumMetipranolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe serum concentration of Metipranolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Metipranolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Metipranolol.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Metipranolol.Experimental
HydralazineHydralazine may increase the hypotensive activities of Metipranolol.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Metipranolol.Approved, Investigational
HydroxychloroquineThe metabolism of Metipranolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Metipranolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Metipranolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Metipranolol.Approved, Investigational
ImidaprilMetipranolol may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Metipranolol.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Metipranolol.Approved
IndalpineThe serum concentration of Metipranolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Metipranolol.Approved
IndenololMetipranolol may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Metipranolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Metipranolol.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Metipranolol.Withdrawn
IpidacrineIpidacrine may increase the bradycardic activities of Metipranolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Metipranolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Metipranolol.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Metipranolol.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Metipranolol.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Metipranolol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Metipranolol.Approved, Investigational, Withdrawn
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Metipranolol.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Metipranolol.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Metipranolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Metipranolol.Approved, Investigational
IvabradineMetipranolol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Metipranolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Metipranolol.Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Metipranolol.Approved
LabetalolLabetalol may increase the hypotensive activities of Metipranolol.Approved
LacidipineMetipranolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideMetipranolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CMetipranolol may increase the bradycardic activities of Lanatoside C.Experimental
LanreotideMetipranolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Metipranolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Metipranolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Metipranolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Metipranolol.Approved, Investigational
LevodopaMetipranolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Metipranolol can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Metipranolol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Metipranolol.Approved, Vet Approved
LinsidomineMetipranolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Metipranolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Metipranolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Lobeline.Investigational
LofexidineMetipranolol may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Metipranolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Metipranolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
LucinactantMetipranolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
MacitentanMetipranolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Metipranolol.Approved
MalathionMalathion may increase the bradycardic activities of Metipranolol.Approved, Investigational
ManidipineMetipranolol may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Metipranolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Metipranolol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Metipranolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Metipranolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Metipranolol.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Metipranolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Metipranolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Metipranolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Metipranolol.Approved, Investigational
MetahexamideMetipranolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Metipranolol.Approved, Investigational, Withdrawn
MethacholineMetipranolol may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Metipranolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Metipranolol.Approved
MethohexitalThe serum concentration of Metipranolol can be decreased when it is combined with Methohexital.Approved
MethoserpidineMetipranolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Metipranolol.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metipranolol.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Metipranolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Metipranolol.Approved, Investigational
MethylergometrineMetipranolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
MethylphenobarbitalThe serum concentration of Metipranolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinMetipranolol may increase the bradycardic activities of Metildigoxin.Experimental
MetoclopramideMetoclopramide may increase the bradycardic activities of Metipranolol.Approved, Investigational
MetoprololMetoprolol may increase the hypotensive activities of Metipranolol.Approved, Investigational
MetyrosineMetipranolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilMetipranolol may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineMetipranolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Metipranolol can be increased when it is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Metipranolol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Metipranolol.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Metipranolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Metipranolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Metipranolol.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Metipranolol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Metipranolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Metipranolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Metipranolol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Metipranolol.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Metipranolol.Approved, Investigational
MuzolimineMetipranolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Metipranolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Metipranolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Metipranolol.Approved
NadololNadolol may increase the hypotensive activities of Metipranolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Metipranolol.Approved
NaftopidilMetipranolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Metipranolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
NebivololMetipranolol may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Metipranolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Metipranolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Metipranolol.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Metipranolol.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Metipranolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Metipranolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Metipranolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Metipranolol.Approved
NiguldipineMetipranolol may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineMetipranolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Metipranolol.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Metipranolol.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Metipranolol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Metipranolol.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Metipranolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Metipranolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Metipranolol.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Metipranolol.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Metipranolol.Approved, Investigational
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Metipranolol.Approved
ObinutuzumabMetipranolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Metipranolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Metipranolol.Approved, Investigational
OleandrinMetipranolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Metipranolol.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Metipranolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Metipranolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Metipranolol.Investigational
OrgoteinOrgotein may decrease the antihypertensive activities of Metipranolol.Vet Approved
OuabainMetipranolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Metipranolol.Approved
OxprenololMetipranolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Metipranolol.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Metipranolol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Metipranolol.Approved, Vet Approved
PalmidrolPalmidrol may decrease the antihypertensive activities of Metipranolol.Experimental, Nutraceutical
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Metipranolol.Approved, Investigational
ParaoxonParaoxon may increase the bradycardic activities of Metipranolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Metipranolol.Approved
PargylinePargyline may increase the hypotensive activities of Metipranolol.Approved
ParoxetineThe serum concentration of Metipranolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
PasireotideMetipranolol may increase the bradycardic activities of Pasireotide.Approved
PenbutololMetipranolol may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe serum concentration of Metipranolol can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Metipranolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Metipranolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Metipranolol.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Metipranolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Metipranolol.Approved
PeruvosideMetipranolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Metipranolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Metipranolol.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Metipranolol.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Metipranolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Metipranolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Metipranolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
PhenylephrineThe therapeutic efficacy of Phenylephrine can be decreased when used in combination with Metipranolol.Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Metipranolol.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Metipranolol.Approved
PindololPindolol may increase the hypotensive activities of Metipranolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metipranolol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Metipranolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Metipranolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Metipranolol.Withdrawn
Platelet Activating FactorMetipranolol may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideMetipranolol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaMetipranolol may increase the bradycardic activities of Poractant alfa.Approved
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Metipranolol.Approved, Withdrawn
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Metipranolol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Metipranolol.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Metipranolol.Approved
PrimaquineThe metabolism of Metipranolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Metipranolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Metipranolol.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Metipranolol.Approved, Investigational
ProchlorperazineThe serum concentration of Metipranolol can be increased when it is combined with Prochlorperazine.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Metipranolol.Experimental
PromazinePromazine may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
PromethazineThe serum concentration of Metipranolol can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
PropafenoneThe risk or severity of adverse effects can be increased when Propafenone is combined with Metipranolol.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Metipranolol.Approved, Investigational
PropiopromazinePropiopromazine may increase the hypotensive activities of Metipranolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Metipranolol.Approved, Investigational, Vet Approved
PropranololMetipranolol may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Metipranolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Metipranolol.Experimental
ProscillaridinMetipranolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Metipranolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Metipranolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Metipranolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Metipranolol.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Metipranolol.Approved
RamiprilRamipril may increase the hypotensive activities of Metipranolol.Approved
RasagilineRasagiline may increase the hypotensive activities of Metipranolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Metipranolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Metipranolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Metipranolol.Approved
RescinnamineMetipranolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Metipranolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Metipranolol.Approved, Experimental, Investigational
RifapentineThe serum concentration of Metipranolol can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Metipranolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Metipranolol.Approved, Investigational
RiociguatMetipranolol may increase the hypotensive activities of Riociguat.Approved
RisperidoneMetipranolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabMetipranolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineMetipranolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Metipranolol.Approved, Investigational, Withdrawn
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Metipranolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Metipranolol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Metipranolol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Metipranolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Metipranolol.Approved
SafrazineSafrazine may increase the hypotensive activities of Metipranolol.Withdrawn
SalbutamolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Metipranolol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Metipranolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Metipranolol.Approved, Investigational, Vet Approved
SalmeterolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Metipranolol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Metipranolol.Approved
SaprisartanMetipranolol may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalThe serum concentration of Metipranolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Metipranolol.Approved, Investigational, Vet Approved
SelexipagMetipranolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Metipranolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Metipranolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Metipranolol.Investigational
SertralineThe serum concentration of Metipranolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Metipranolol.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Metipranolol.Approved, Investigational
SitaxentanMetipranolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Metipranolol.Approved
SpiraprilMetipranolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Metipranolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Metipranolol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Metipranolol.Approved, Investigational
SufentanilSufentanil may increase the bradycardic activities of Metipranolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Metipranolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Metipranolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Metipranolol.Experimental
TacrineTacrine may increase the bradycardic activities of Metipranolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Metipranolol.Approved, Investigational
TafenoquineThe metabolism of Metipranolol can be decreased when combined with Tafenoquine.Approved, Investigational
TalinololMetipranolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Metipranolol.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Metipranolol.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Metipranolol.Approved, Investigational
TemocaprilMetipranolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Metipranolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Metipranolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Metipranolol.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Metipranolol.Approved
TerbinafineThe metabolism of Metipranolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Metipranolol.Approved
TerlipressinMetipranolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineMetipranolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Metipranolol.Approved, Investigational, Withdrawn
TheodrenalineMetipranolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Metipranolol.Approved
ThiamylalThe serum concentration of Metipranolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Metipranolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Metipranolol.Withdrawn
ThiopentalThe serum concentration of Metipranolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Metipranolol.Approved
ThioridazineThioridazine may increase the hypotensive activities of Metipranolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Metipranolol.Approved
TiboloneMetipranolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenMetipranolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Metipranolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Metipranolol.Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Metipranolol.Approved, Investigational
TofacitinibTofacitinib may increase the bradycardic activities of Metipranolol.Approved, Investigational
TolazamideMetipranolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
TolbutamideMetipranolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metipranolol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Metipranolol.Approved
TolonidineMetipranolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Metipranolol.Approved
TorasemideTorasemide may increase the hypotensive activities of Metipranolol.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Metipranolol.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Metipranolol.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Metipranolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Metipranolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Metipranolol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Metipranolol.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Metipranolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Metipranolol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Metipranolol.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Metipranolol.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Metipranolol.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Metipranolol.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Metipranolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Metipranolol.Approved
TyrothricinTyrothricin may increase the bradycardic activities of Metipranolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Metipranolol.Approved, Investigational
UnoprostoneMetipranolol may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Metipranolol.Investigational
ValaciclovirThe risk or severity of adverse effects can be increased when Metipranolol is combined with Valaciclovir.Approved, Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Metipranolol.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Metipranolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Metipranolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Metipranolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Metipranolol.Approved
VincamineMetipranolol may increase the hypotensive activities of Vincamine.Experimental
XipamideMetipranolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineMetipranolol may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Metipranolol.Approved, Investigational, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Metipranolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Metipranolol can be increased when it is combined with Zimelidine.Withdrawn
ZofenoprilMetipranolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Metipranolol.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015345
KEGG Drug
D02374
KEGG Compound
C07915
PubChem Compound
31477
PubChem Substance
46505935
ChemSpider
29193
ChEBI
6897
ChEMBL
CHEMBL1291
Therapeutic Targets Database
DAP000480
PharmGKB
PA164748727
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Metipranolol
ATC Codes
C07BA68 — Metipranolol and thiazides, combinationsS01ED04 — MetipranololS01ED54 — Metipranolol, combinations

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Alcon Laboratories
  • Bausch & Lomb Inc.
  • Dispensing Solutions
  • Doctor Gerhard Mann Chemisch Pharmazeutische Fabrik GmbH
  • Falcon Pharmaceuticals Ltd.
  • Physicians Total Care Inc.
Dosage forms
FormRouteStrength
Solution / dropsOphthalmic3 mg/mL
Prices
Unit descriptionCostUnit
Optipranolol 0.3% Solution 10ml Bottle42.99USD bottle
Optipranolol 0.3% Solution 5ml Bottle25.99USD bottle
Optipranolol 0.3% eye drops5.08USD ml
Metipranolol 0.3% eye drops3.55USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)105-107 °CPhysProp
water solubility589 mg/LNot Available
logP2.66MANNHOLD,R ET AL. (1990)
Predicted Properties
PropertyValueSource
Water Solubility0.173 mg/mLALOGPS
logP2.13ALOGPS
logP2.74ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.79 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity86.63 m3·mol-1ChemAxon
Polarizability35.85 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8638
Blood Brain Barrier-0.9906
Caco-2 permeable-0.5988
P-glycoprotein substrateSubstrate0.6335
P-glycoprotein inhibitor INon-inhibitor0.7599
P-glycoprotein inhibitor IINon-inhibitor0.8296
Renal organic cation transporterNon-inhibitor0.9097
CYP450 2C9 substrateNon-substrate0.8014
CYP450 2D6 substrateSubstrate0.5086
CYP450 3A4 substrateNon-substrate0.6564
CYP450 1A2 substrateNon-inhibitor0.6333
CYP450 2C9 inhibitorNon-inhibitor0.8721
CYP450 2D6 inhibitorNon-inhibitor0.7104
CYP450 2C19 inhibitorNon-inhibitor0.9547
CYP450 3A4 inhibitorNon-inhibitor0.8282
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9528
Ames testNon AMES toxic0.9219
CarcinogenicityNon-carcinogens0.9205
BiodegradationNot ready biodegradable0.7546
Rat acute toxicity2.1686 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9794
hERG inhibition (predictor II)Non-inhibitor0.7745
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol esters. These are aromatic compounds containing a benzene ring substituted by a hydroxyl group and an ester group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol esters
Sub Class
Not Available
Direct Parent
Phenol esters
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Secondary alcohols / Carboxylic acid esters / Amino acids and derivatives / 1,2-aminoalcohols / Monocarboxylic acids and derivatives / Dialkylamines / Organopnictogen compounds
show 3 more
Substituents
Phenol ester / Phenoxy compound / Phenol ether / Alkyl aryl ether / Monocyclic benzene moiety / 1,2-aminoalcohol / Amino acid or derivatives / Carboxylic acid ester / Secondary alcohol / Carboxylic acid derivative
show 15 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, acetate ester, secondary amino compound, propanolamine (CHEBI:6897)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Drimal J, Knezl V, Magna D, Strizova K: External transport of beta-adrenergic binding sites in ischemic myocardium. Gen Physiol Biophys. 1987 Dec;6(6):583-91. [PubMed:2895037]
  4. Noack E: [Antiglaucomatous effectiveness of beta receptor blockers with special reference to metipranolol]. Klin Monbl Augenheilkd. 1986 Jul;189(1):1-3. [PubMed:2876128]
  5. Arai K, Wood JP, Osborne NN: Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms. Brain Res. 2003 Sep 26;985(2):176-86. [PubMed:12967722]
  6. Bilcikova L, Bauer V, Kolena J: The action of adrenoceptor agonists and antagonists on the guinea pig and dog trachea. Gen Physiol Biophys. 1987 Feb;6(1):87-101. [PubMed:2885244]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Drimal J, Knezl V, Magna D, Strizova K: External transport of beta-adrenergic binding sites in ischemic myocardium. Gen Physiol Biophys. 1987 Dec;6(6):583-91. [PubMed:2895037]
  4. Arai K, Wood JP, Osborne NN: Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms. Brain Res. 2003 Sep 26;985(2):176-86. [PubMed:12967722]
  5. Bilcikova L, Bauer V, Kolena J: The action of adrenoceptor agonists and antagonists on the guinea pig and dog trachea. Gen Physiol Biophys. 1987 Feb;6(1):87-101. [PubMed:2885244]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A: Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):981-1007. doi: 10.1517/17425255.2.6.981 . [PubMed:17125412]
  2. Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. [PubMed:14732961]
  3. Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, Komura H: Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. doi: 10.1016/j.dmpk.2016.08.007. Epub 2016 Sep 2. [PubMed:27836712]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:44